Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
It is well established that direct oral anticoagulants (DOACs) are the cornerstone of anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and should be preferred over vitamin K antagonists (VKAs) since they are superior or non-inferior to VKAs in reducing thromboembolic risk and are associated with a lower risk of intracranial hemorrhage (IH). In addition, many factors, such as fewer pharmacokinetic interactions and less need for monitoring, contribute to the favor of this therapeutic strategy. Although DOACs represent a more suitable option, several issues should be considered in clinical practice, including drug-drug interactions (DDIs), switching to other antithrombotic therapies, preprocedural and postprocedural periods, and the use in patients with chronic renal and liver failure and in those with cancer. Furthermore, adherence to DOACs appears to remain suboptimal. This narrative review aims to provide a practical guide for DOAC prescription and address challenging scenarios.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531873 | PMC |
| http://dx.doi.org/10.3390/jcm12185955 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phage-nanomaterial platforms for precision antimicrobial therapy: from design to therapeutic application.
Nanoscale
September 2025
Institute of Health Innovation & Technology, National University of Singapore, Singapore, 117599, Singapore.
The rapid increase in multidrug-resistant (MDR) bacteria and biofilm-associated infections has intensified the global need for innovative antimicrobial strategies. Phage therapy offers promising precision against MDR pathogens by utilizing the natural ability of phages to specifically infect and lyse bacteria. However, their clinical application is hampered by challenges such as narrow host range, immune clearance and limited efficacy within biofilms.
View Article and Find Full Text PDFBiomechanical impact of sagittal curvature radius in glenoid fossa on TMJ prosthesis performance: A finite element study of custom designs.
J Prosthet Dent
September 2025
Full Professor, School of Mechanical Engineering, Universidad Industrial de Santander, Bucaramanga, Colombia. Electronic address:
Statement Of Problem: Although custom temporomandibular joint (TMJ) prostheses manufactured via computer-aided design and manufacturing (CAD-CAM) and produced through 3-dimensional (3D) printing or computer numerical control (CNC) allow for sagittal curvature adjustments in the glenoid fossa, their design remains unregulated by the Food and Drug Administration. Consequently, the geometry is determined largely by the engineer's discretion, with limited biomechanical evidence to guide these decisions. The lack of validation regarding how sagittal curvature influences joint stress distribution under various anatomical and functional conditions represents a gap in current knowledge that warrants investigation.
View Article and Find Full Text PDFOff-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial.
Heart
September 2025
Department of Cardiology, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.
Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.
Oral anticoagulation in patients with atrial fibrillation and heart valve prosthesis: a substudy from the LAAOS III Trial.
J Thorac Cardiovasc Surg
September 2025
Population Health Research Institute, Hamilton Health Sciences, McMaster University, Ontario, Canada.
Objective: Societal guidelines recommend vitamin K antagonists (VKAs) for atrial fibrillation patients with recent biological valve implantation, but the safety and efficacy of direct oral anticoagulants (DOACs) in this setting remain uncertain, especially in the early postoperative period. This substudy of the Left Atrial Appendage Occlusion Study (LAAOS) III trial aimed to compare thromboembolic and bleeding outcomes in patients discharged on VKAs versus DOACs after bioprosthesis implantation or mitral valve repair.
Methods: A total of 2,645 patients were included, with 461 discharged on DOACs and 2184 on VKAs.
Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome.
Biomed Pharmacother
September 2025
Department of Biomedical Sciences and Institute for Medical Science, Jeonbuk National University Medical School, Jeonju, Jeonbuk 54907, South Korea. Electronic address:
Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne Dabie bandavirus (DBV), is a serious public health concern due to its high morbidity and mortality rates. However, no antiviral treatment has been developed for SFTS. Through target-focused screening, we identified five anti-SFTS candidates: niclosamide (NIC), cepharanthine, nifedipine, zanamivir, and ivacaftor.
View Article and Find Full Text PDF